The HOX genes are a family of closely related transcription factors that help to define the identity of cells and tissues during embryonic development and which are also frequently deregulated in a number of malignancies, including breast cancer. While relatively little is known about the roles that individual HOX genes play in cancer, it is however clear that these roles can be both contradictory, with some members acting as oncogenes and some as tumor suppressors, and also redundant, with several genes essentially having the same function. Here, we have attempted to address this complexity using the HXR9 peptide to target the interaction between HOX proteins and PBX, a second transcription factor that serves as a common co-factor for many HOX proteins. We show that HXR9 causes apoptosis in a number of breast cancer-derived cell lines and that sensitivity to HXR9 is directly related to the averaged expression of HOX genes HOXB1 through to HOXB9, providing a potential biomarker to predict the sensitivity of breast tumors to HXR9 or its derivatives.
Introduction
The HOX genes are a family of homeodomain-containing transcription factors that were first identified as determinates of cell and tissue identity in early development, although they are now also known to function in adult stem cell renewal and differentiation [1] [2] [3] . A series of duplication events is thought to have given rise to the four separate clusters of HOX genes found in vertebrates, with each cluster consisting of a group of closely linked members that often share enhancer regions. These clusters are named A, B, C, and D, and together they contain the 39 HOX genes found in mammals [4] . Each gene within a cluster is labeled with a number according to their relative position in the chromosome, so for example HOXB1 is the 3 0 most member of the B cluster, and HOXB13 is the 5 0 most member [5] . The linkage of genes within each cluster is closely reflected in both their temporal and spatial order of expression in the embryo, with the 3 0 genes being expressed more anteriorly and earlier than their 5 0 neighbors. The relative position within the cluster is also reflected in the co-factor interactions, DNA binding specificity and regulation of each member [4] .
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In addition to a role in development, and subsequently in stem cell differentiation, the HOX genes are also frequently deregulated in a number of cancers including melanoma, mesothelioma, and lung, kidney, prostate, ovarian, and breast cancer [6] . Their function in oncogenesis is still unclear; however, it is apparent that the great complexity of HOX function in development is also reflected in oncogenesis, with some HOX genes functioning as tumor suppressors and others as oncogenes. The best known examples of both have been identified in breast cancer, where HOXA5 is known to function as a tumor suppressor [7] , at least in part through activating the transcription of the key tumor-suppressor gene TP53 [8] . Conversely, members of the closely related HOXB genes including HOXB5 and HOXB7 are oncogenic through mechanisms which include an up regulation of FGF2 [9] , and the promotion of epithelial to mesenchymal transition [10] . HOXB7 has also been shown to confer tamoxifen resistance through activation of the EGFR pathway [11] . Exactly how such similar transcription factors can have opposing functions is also unclear, although it may be related to differential co-factor binding and consequently differential regulation of target genes. Known co-factors include members of the PBX, MEIS, and PREP families of transcription factors all of which can influence the binding selectivity of HOX proteins and their action as either a suppressor or activator of transcription [3] . As an additional complexity, HOX proteins can also regulate transcription through binding to DNA as monomers [12] .
While different HOX genes can have individual, specific functions in embryonic development, there is generally a high level of functional redundancy, especially with regards to fundamental and highly conserved patterning events such as anterior-posterior pattering of the spine and hindbrain [13, 14] . This is also true in cancer, where a similar oncogenic function is common to a number of HOX genes, especially HOXB1 through to HOXB9 [14, 15] .
This mixture of opposing functionality and functional redundancy, combined with the lack of ligand binding sites, makes targeting HOX genes in cancer potentially very difficult. One approach however is to target multiple groups of HOX genes in a way that also singles out specific HOX functions, something that could potentially be achieved by disrupting the binding of HOX proteins to specific co-factors. To date this has only been possible for the PBX co-factor that can bind to HOX proteins numbered 1-9 [15] [16] [17] [18] [19] . PBX increases the nuclear translocation of HOX proteins and also influences the selection of DNA binding sites [20, 21] . Its interaction with HOX is mediated by a highly conserved hexapeptide region on HOX proteins [20] [21] [22] [23] and previous studies have shown that a synthetic peptide consisting of these amino acids and a short polyarginine sequence, known as HXR9, is capable of blocking the interaction between HOX and PBX proteins both in vitro and in vivo. HXR9 causes apoptosis in a number of cancers including melanoma [15] , myeloma [18] , and kidney [16] , non-small cell lung [17] , and ovarian cancer [19] . Here we show that HXR9 also causes apoptosis in cell lines derived from different breast cancers, and that HXR9 specifically blocks the oncogenic function of HOX genes without blocking the known tumor-suppressor role of HOXA5. Importantly, we also show that there is an extremely high-correlation between the average expression of HOX genes HOXB1 through HOXB9 and the sensitivity of cell killing by HXR9.
Materials and methods

Cell lines and culture
The cell lines used in this study are listed in Supplementary Table 1. They were obtained from the ATCC through LGC Standards Ltd. (UK), and were cultured according to the instructions on the LGC Standards website.
Synthesis of HXR9 and CXR9 peptides HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide sequence that can bind to PBX and nine C-terminal arginine residues (R9) that facilitate cell entry [15] . The N-terminal and C-terminal amino bonds are in the D-isomer conformation, which has previously been shown to extend the half life of the peptide to 12 h in human serum [15] . CXR9 is a control peptide that lacks a functional hexapeptide sequence but which includes the R9 sequence. All peptides were synthesized using conventional column based chemistry and purified to at least 80 % (Biosynthesis Inc., USA).
Imaging of cell cultures
Cells were plated in 6-well plates using 2 ml of medium and allowed to recover for at least 24 h. When approximately 60 % confluent, cells were treated with the active peptide HXR9 (60 lM) or the control peptide CXR9 (60 lM) for 3 h. For phase contrast micrographs, the cells were washed twice with cold PBS and visualized using a Nikon Eclipse TS100 inverted microscope and images recorded using a Nikon camera and capture software (Jencons).
Analysis of cell death and apoptosis
Cells were treated with HXR9 or CXR9 as described above. Assessment of cell viability was done using the MTS assay (Promega) according to the manufacturer's instructions. Cells were harvested by incubating in Trypsin-EDTA (Sigma) at 37°C until detached and dissociated. Apoptotic cells were identified using flow cytometry (Beckman Coulter Epics XL Flow) and the Annexin V-PE apoptosis detection kit (BD Pharmingen) as described by the manufacturer's protocol. Caspase-3 activity was measured using the EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the protocol defined by the manufacturer.
RNA purification and reverse transcription
Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen) by following the manufacturer's protocol. The RNA was denatured by heating to 65°C for 5 min. cDNA was synthesized from RNA using the Cloned AMV First Strand Synthesis Kit (Invitrogen) according to the manufacturer's instructions.
Quantitative PCR
Quantitative PCR was done using the Stratagene MX3005P real-time PCR machine and the Brilliant SYBR Green QPCR Master Mix (Stratagene). Oligonucleotide primers were designed to facilitate the unique amplification of b-actin, c-Fos, TP53, and each HOX gene.
Transcriptional profiling
Total RNA was extracted from SKBR3 cells treated with CXR9 or HXR9 (60 lM) for 3 h, and was used as a template to generate Cy3-labeled cRNA using the Low RNA Input Linear Amplification Kit (Agilent). Each Cy3-cRNA was used as a probe on the Whole Human Genome Microarray (4944K) slide. This microarray consists of 60-mer oligonucleotides with sequences representing more than 41,000 human genes. The microarray slides were scanned and data were extracted using the Agilent Feature Extraction Software (version 9.5.3). Data was analyzed using GeneSpring GX software. The full data set and further experimental details have been deposited in the Array Express repository; accession number E-MEXP-3634.
Mice and in vivo trial
All animal experiments were conducted in accordance with the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the Welfare of Animals in Experimental Neoplasia [24] and were approved by the University of Surrey Research Ethics Committee. The mice were kept in positive pressure isolators in 12 h light/ dark cycles and food and water were available ad libitum.
Athymic nude mice were inoculated subcutaneously with a suspension of 2.5 9 10 6 MDA-MB231 cells in culture media (100 ll). Once tumors reached volumes of approximately 100 mm 3 , mice received an initial dose of 100 mg/kg CXR9 or HXR9 intratumorly, with subsequent dosing when or if the tumor reoccurred. Each treatment group contained 10 mice. The mice were monitored carefully for signs of distress, including behavioral changes and weight loss. Patients had given consent for the inclusion of their tissue in this bank; individual permission from each patient was not subsequently required for the particular study described here. Frozen sections were cut and using a stained guide slide, malignant cells were dissected from the surrounding tissue. RNA was extracted using the AllPrep DNA/RNA Micro kit (Qiagen). The manufacturer instructions were followed with the exception of an enhanced homogenization step.
Results
HOX gene expression in breast cancer cell lines and normal breast tissue
In order to assess the expression of HOX genes in breast cancer and in normal breast tissue five breast cancerderived cell lines were used, SKBR3, MB231, MCF7, ZR75.1 and UACC, together with MCF10a, derived from a non-malignant mammary epithelium (detailed in Online resource 4). RNA was extracted from cultures of each of these, together with normal breast tissue. HOX expression was determined by semi-quantitative PCR, and calculated as a ratio with the expression of the house keeping gene GAPDH (Fig. 1 ). This reveals a significant, but variable degree of HOX deregulation between breast cancers derived cell lines and normal breast tissue, with normal breast tissue and the non-malignant cell line MCF10a generally having lower expression than the cancer-derived cell lines.
HXR9 is toxic to breast cancer cells
Previous studies have indicated that HXR9 is taken up by and is selectively cytotoxic to cancer cells. A fluorescently labeled derivative of HXR9 was incubated with MDA-MB231 cells and localized to both the cytoplasm and the nucleus (Fig. 2a) . In order to determine the IC50 for cell killing by HXR9 we used an MTS assay at varying concentrations of the peptide. This indicated that the IC50 for cell killing for SKBR3, MDA-MB231, MCF7, ZR75.1, UACC, and MCF10a were 16, 23, 33, 42, 48 and 51 lM, respectively. Thus, MCF10a and the breast cancer-derived cell lines UACC, ZR75.1, and MCF7 are relatively insensitive to HXR9 while MDA-MB231 and SKBR3 are significantly more sensitive (p \ 0.01; Fig. 2b ). As a control a second peptide was used, CXR9, which has an identical polyarginine cell penetrating sequence to HXR9 but which lacks an active hexapeptide sequence. None of the cell lines were sensitive to CXR9 (i.e., IC50 [ 100 lM).
Treatment with HXR9 increases the expression of cFos but not TP53
Previous studies have shown that HOX genes can prevent apoptosis, at least in part, by blocking the expression of cFos, and that HXR9 can induce apoptosis by mediating a rapid increase in the number of cFos transcripts [15] . SKBR3 and M cells similarly show a very large increase in cFos expression (553-fold) 2 h after HXR9 treatment (Fig. 3) . Conversely, some HOX genes have been identified as potential tumor suppressors in breast cancer. Most notable among these is HOXA5, which functions at least in part through its regulation of TP53 [8] . The detailed mechanism for this regulation is yet to be elucidated, but if it requires a HOXA5/PBX dimer then it might be expected that HXR9 could reduce TP53 expression and therefore be pro-oncogenic in this respect. In order to determine whether this is the case we assayed TP53 expression in SKBR3 and MDA-MB231 cells treated with HXR9 by Quantitative PCR. This revealed that there is no significant change in TP53 expression in response to HXR9 treatment in either cell line (Fig. 3) . Similar changes were also found to occur at the protein level using western blotting (Fig. 3 ).
HXR9 primarily causes transcriptional activation
In order to identify additional target genes that are regulated by a HOX/PBX dimer, and are thus differentially expressed upon treatment with HXR9, we used whole genome based microarray to study the transcriptome of HXR9 treated SKBR3 cells. This revealed that the majority of HXR9 target genes identified are upregulated by HXR9 treatment (Online resource 1), indicating that the HOX/ PBX dimers act predominantly to repress transcription in these cells. The promoter regions of the 20 genes that are most strongly upregulated by HXR9 were analyzed for the presence of the HOX/PBX binding consensus [25] . Of these 20 genes 18 had at least one potential site, and many of the promoter regions had multiple and often overlapping consensus binding sites (Online resource 2), including ATF3, NR4A3, ZFP36, and PPP1R15A, that have tumorsuppressor functions (Online resource 5). Furthermore, among those genes that were upregulated by tenfold or more, 22 have known tumor-suppressor function.
HXR9 induces apoptosis
The mechanism of cell death was studied in the most sensitive of six cell lines, SKBR3. Previous studies have shown that HXR9 can induce apoptosis through, at least in part, a rapid increase in expression of cFos [15] . SKBR3 and MDA-MB231 cells similarly show a very large increases in cFos expression (553-and 19.3-fold, respectively) 2 h after HXR9 treatment (Fig. 3) . In order to establish whether HXR9 induces apoptosis, HXR9 treated cells were analyzed by FACS after staining with Annexin-7AAD and propidium iodide. The former allows the detection of changes in the cell membrane that are characteristic of apoptosis, while the later is used to evaluate membrane integrity (Fig. 4a) . This shows that HXR9 treated SKBR3 undergo cell death predominantly through apoptosis, with the majority of cells being in an early stage of apoptosis 2 h after HXR9 treatment (Fig. 4b) . There is also a corresponding increase in Caspase 3 activity over 2 h with the same concentration of HXR9 (Fig. 4c) . Similar results were obtained for the MDA-MB231 cell line (not shown).
Sensitivity to HXR9 correlates with HOX expression
As HXR9 targets the HOX/PBX interaction, we calculated the average expression of all HOX genes numbered between 1 and 9 (i.e., the 3 0 most 27 members of the HOX family that bind PBX), for all of the cell lines and for normal breast tissue. When ranked against sensitivity to HXR9 there is an apparent positive relationship between mean HOX expression and IC50 with the exception of MCF7 (Fig. 5a) . However, when cell line sensitivity is ranked against mean expression of only the HOX genes HOXB1 through to HOXB9 the ranked order is complete (Fig. 5b) . When mean expression of HOXB1 through HOXB9 is plotted against the IC50 for HXR9 toxicity a linear relationship is apparent, the line of regression for this putative relationship has an r 2 value of 0.9778 (p = 0.0002, Fig. 5c ).
HOX genes HOXB1 through to HOXB9 are highly expressed in a subset of primary breast tumors In order to explore the possible relevance of these findings to primary tumors we measured the transcripts of HOX genes HOXB1 through to HOXB9 in 78 primary tumor samples obtained from the GST Breast Tissue and Data Bank, the associated pathological characteristics of which are listed in Online resource 6. This revealed that while the majority of tumors expressed these genes to a relatively low level, a subset (7.4 %) showed a highly elevated level of expression that could indicate that these cells would be sensitive to killing by HXR9 (i.e., with an IC50 \ 1 lM, Fig. 5d ). High levels for HOXB1 through to HOXB9 expression did not correlate with expression of the estrogen receptor (ER), progesterone receptor (PR), or HER2, nor with survival, tumor grade, or spread to axillary lymph nodes (Online resource 3). There was however a positive association between low HOXB1 through to HOXB9 expression and mucoid or lobular histology (Online resource 3).
HXR9 retards tumor growth in vivo
In order to assess the efficacy of HXR9 in vivo we established a xenograft model of MDA-MB231. Although these cells are less sensitive to killing by HXR9 than SKBR3, it is more widely used as a xenograft model (605 references in PubMed compared to 35 for SKBR3), and represents a form of breast cancer with a poor prognosis, having been 9778. The probability for the null hypothesis that the slope of the line is actually zero was calculated as to be p = 0.0002. NBT normal breast tissue. d The distribution of mean HOXB1 through to HOXB9 expression in primary tumors. The expression of these genes in 78 primary tumors (red) were plotted according to their theoretical sensitivity to HXR9, as determined using the linear regression described above. The regression line shown in part c is included for reference derived from a tumor negative for HER2, ER, and PR [26] . Tumors were initiated by injection of cells into the flank, and treatment was started when the average tumor volume had reached 100 mm 3 with an initial dose of HXR9 of 20 mg/kg intratumorally, followed by an additional dose if tumor growth reoccurred (with no more than one additional dose per animal). Tumor growth in HXR9 treated mice was retarded 7.5-fold at 13 days compared to the control group (Fig. 6a) , and the HXR9 treated animals survived for significantly longer (88 % survival at 30 days as compared to 0 % for the control group, p = 0.004; Fig. 6b ) RNA was extracted from tumors at the end of 32 days to measure cFos expression by QPCR; cFos was found to be expressed at an 18-fold higher level in tumors from HXR9 treated mice than in tumors from untreated mice (Fig. 6c) . Histological analysis of CXR9 and HXR9 treated tumors revealed extensive cell death in the later (Fig. 6d) .
Discussion
In this study we have shown that HOX genes are generally deregulated in breast cancer, and mostly there is an increase in expression when compared to normal breast tissue or non-malignant MCF10a cells, although the exact pattern of expression varies between cell lines. The significance of the variation between cell lines is unclear, although the functional redundancy between HOX genes may mean that the net effect of HOX over expression is similar. There are however cases where cancer phenotype can be determined by specific HOX genes, for example in ovarian cancer HOXA11 expression confers a mucinous (as opposed to serous) phenotype [27] , and distinct patterns of HOX expression are associated with lymphoblastoid myeloma [18] .
We also show that treating breast cancer cell lines with the HOX/PBX inhibitor HXR9 causes apoptosis in SKBR3 and is cytotoxic to all of the lines tested. This suggests, as it has done in studies on other cancers, that targeting the HOX/PBX dimer allows a specific subset of HOX functions to be modified, one of which includes the repression of apoptosis [15] [16] [17] [18] [19] . In the case of melanoma, apoptosis is induced in part through the induction of cFos [15] , and a large increase in cFos expression is also observed in this study when SKBR3 cells are treated with HXR9. Selective targeting of anti-apoptotic functions is important as some HOX genes, notably HOXA5 in breast cancer [8] , have a tumor-suppressor role rather than an oncogenic role. This is at least partly mediated by an increase in TP53 expression [8] , however we show here that HXR9 does not change TP53 expression in breast cancer cells, suggesting that the regulation of TP53 by HOXA5 does not depend upon a HOXA5/PBX dimer, but may instead be dependant on other co-factors, or may possibly not require a co-factor. The later possibility is supported by the observation that forced expression of HOXA5 alone is sufficient to drive TP53 transcription, and that the HOXA5 binding site identified in the TP53 promoter does not appear to include a PBX binding consensus [8] . Further, while confirming a positive interaction between HOXA5 and TP53, a more recent study also suggests that TP53 is not transcriptionally regulated by HOXA5 [28] . These findings support the conclusions of previous studies that indicate the HOX/PBX dimers are predominantly anti-apoptotic in the context of cancer [15] [16] [17] [18] [19] .
An oncogenic role for HOX/PBX dimers is also supported by the transcriptional repression of genes with known tumor-suppressor functions, all of which exhibit a correspondingly large increase in expression upon HXR9 treatment (Online resource 5). These include EGR2 [29] and ATF3 [30] , both of which function in p53 mediated apoptosis, the GTPase encoding gene RRAD which is frequently lost in malignancy [31] , and the EGFR/ERBB2 inhibitor ERRFI1 [32] . These findings are of particular interest because they suggest potential synergistic interactions between HXR9 and other classes of drug.
Identifying patients that are likely to respond to a particular treatment is a now a key requirement in clinical trials, and the development of predictive biomarkers for this purpose is most effective at early drug development stages. We hypothesized that sensitivity to HXR9 in breast cancer lines should depend, at least to some extent, on HOX gene expression. Given the functional redundancy found in the PBX binding HOX proteins, we examined whether sensitivity might depend on the averaged level of HOX gene expression. In fact, our results suggest that this is not the case. However, the averaged expression level of a subset of HOX genes, namely HOXB1 through HOXB9, does correlate with sensitivity to HXR9 with a highly significant line of regression. High levels of HOXB1 through HOXB9 expression are associated with increased sensitivity to killing by HXR9, while low levels of expression are associated with insensitivity to HXR9. Here, we show that both normal breast tissue and the nonmalignant mammary line MCF10a have relatively low levels of expression, and the later is also relatively resistant to HXR9 mediated cell killing.
Conclusions
The significance of these finding requires further study, although we note that HOXB genes have in general been more frequently implicated as having a role in cancer, both through direct mechanistic studies [6] and through a number of clinical observations including the association of elevated HOXB7 expression with a poor prognosis in HER2 positive breast cancer [33] . Our analysis of 78 primary breast tumors showed that while the majority had relatively low levels of HOXB1 through to HOXB9 expression, a subset had very highly elevated expression of these genes, indicating that they could potentially be extremely sensitive to HXR9. Determining the expression of these genes from biopsies could form the basis by which patients might be selected for treatment by HXR9, or its derivative.
